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Available online 27 November 2015AbstractBackground: Skeletal muscle is a major target of thyroid hormone action. Although sarcopenia is associated with adverse health outcomes in the
elderly, few studies have examined the association between sarcopenia and thyroid hormone levels in elderly Asians. We investigated the
relationship between thyroid hormone levels and sarcopenia in elderly Koreans.
Methods: 658 individuals (324 males and 334 females) 60 years old who visited the Health Screening and Promotion Center at Ajou
University Hospital were recruited for the study. Whole-body dual-energy X-ray absorptiometry was performed, and gait speed and hand grip
strength were measured. The rate and odds ratios for sarcopenia were calculated for free thyroxine (fT4) and thyroid stimulating hormone
(TSH) levels.
Results: The fT4 concentration was negatively associated with muscle mass in males (r2 ¼ 0.031, p ¼ 0.001) and females (r2 ¼ 0.019,
ps ¼ 0.011). The highest rate of sarcopenia occurred in the highest fT4 quartile in males and females. However, no significant differences were
found among TSH quartiles in either sex. TSH was not significantly associated with the risk of sarcopenia in males or females, whereas the fT4
concentration was associated with the risk of sarcopenia in both sexes.
Conclusions: Higher fT4 levels, not lower TSH levels might have an adverse effect on sarcopenia especially in elderly people.
© 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Ageing is a global phenomenon. The advanced-age popu-
lation within the Organisation for Economic Co-operation and
Development (OECD) region outnumbered the youngest
population (0e19 years old) in 2010 and is expected to surpass
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).faster than any other country in the OECD. In 2010, ~10% of
the population was >65 years of age, and that proportion is
estimated to be ~40% by 2050 [1].
Hypothyroidism and hyperthyroidism are common among
the general population and are more prevalent in individuals
aged >60 years [2,3]. Early diagnosis and treatment of overt
thyroid dysfunction is crucial for this population in view of the
marked effects of abnormal circulating thyroid hormone levels
on a number of organ systems, including the heart, skeleton,
and neurological systems [4]. Hypothyroidism is associated
with impaired cognitive function [5] and medical conditions,
such as hyperlipidemia, congestive heart failure, and macro-
cytic anemia, in the elderly population [6,7]. Furthermore,Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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increased risks of cardiovascular disease, osteoporosis, and
mortality, particularly among elderly individuals [4,7].
Sarcopenia is the age-associated loss of skeletal muscle
mass resulting in decreased strength and aerobic capacity,
leading to reduced functional capacity [8]. Previous studies
have shown an association between sarcopenia and adverse
health outcomes, such as falls, disability, hospital admission,
long-term care placement, poor quality of life, and mortality,
which highlights the importance of detecting and treating
sarcopenia in older individuals [9].
Skeletal muscle is a major target of thyroid hormone action
as demonstrated by the myopathic symptoms observed in pa-
tients with thyroid function disorders [10]. Hyperthyroidism
can affect limb muscle mass and strength [11]. However, few
studies have investigated the association of sarcopenia with
thyroid hormone concentrations in the elderly Asian popula-
tion. We investigated the relationship between thyroid hor-
mone levels and the rate of sarcopenia in healthy Korean
males and females 60 years old.
2. Materials and methods2.1. SubjectsWe recruited individuals aged 60 years who visited the
Health Screening and Promotion Center at Ajou University
Hospital (Suwon, Republic of Korea) for a routine medical
examination between April 2011 and July 2014. Whole-body
dual-energy X-ray absorptiometry (DXA) was performed,
and gait speed and hand grip strength were measured in 666 of
747 participants. We excluded five individuals who were
diagnosed with thyroid disease and currently taking thyroid
hormone or anti-thyroid drugs and three individuals without
thyroid hormone concentration measurements. Thus, 658
subjects (324 males, 334 females) were included in the study.
Informed consent was obtained from all participants. Our
study was approved by the Institutional Review Board of Ajou
University Hospital (IRB number: AJIRB-MED-MDB-11-
034).2.2. Anthropometric parameters, grip strength, and gait
speed measurementsHeight and body weight were measured using standard
methods, with subjects wearing light clothing. Body mass
index (BMI) was calculated as weight divided by height
squared (kg/m2). Waist circumference was measured midway
between the lower rib margin and the iliac crest in a standing
position. Blood pressure was measured after resting for 10 min
in a sitting position using an automatic sphygmomanometer
(TM-2655P; P.M.S (Instruments) Ltd., Berkshire, UK).
Appendicular skeletal muscle masses (ASM) were acquired
using DXA (Lunar iDXA, the GE Healthcare Lunar, Madison,
WI, USA). ASM was calculated as the sum of muscle mass in
arms and legs, assuming that all non-fat and non-bone tissue is
skeletal muscle. Daily quality control scans were performedduring the study period. Subjects were scanned using standard
imaging and positioning protocols. Muscle strength was
assessed by grip strength, which was measured using a Jamar®
Plus Digital Hand Dynamometer (Sammons, Preston, IL,
USA). Testing was performed with the participant in the
sitting position with the elbow flexed at 90. Measurements
were taken for each hand, and the participant was encouraged
to exert the greatest force possible. The strongest hand-grip
strength was used in the analyses. Physical performance was
assessed by usual walking speed. Participants were asked to
walk straight for 8 feet (2.4 m) at their usual speed.2.3. Laboratory measurementsFasting blood samples were drawn at the antecubital area
between 08.00 and 11.00 h. Serum samples were stored at 4 C
and analyzed within 1 day after sampling. Blood urea nitro-
gen, fasting glucose, liver enzymes, and lipid profiles were
measured using an automatic analyzer (Toshiba TBA 200FR;
Toshiba Medical System Co. Ltd, Tochigi-ken, Japan). Low-
density lipoprotein cholesterol levels were calculated from
the levels of total cholesterol, triglycerides (TG) and high-
density lipoprotein cholesterol. The concentration of 25-hy-
droxyl vitamin D was assayed using a radioimmunoassay kit
(DiaSorin, Stillwater, MN, USA). Thyroid stimulating hor-
mone (TSH) and free thyroxine (fT4) levels were measured
using enzyme immunoassays (Advia Centaur Immunodiag-
nostic system, Siemens Healthcare Diagnostics, Tarrytown,
NY, USA). The reference ranges were 0.55e4.78 uIU/mL for
TSH and 0.89e1.76 ng/dL for fT4.2.4. CovariatesThe participants completed standardized questionnaires on
smoking and drinking status, medication history, and medical
histories of hypertension, type 2 diabetes, and cardiovascular
and cerebrovascular diseases. Smoking history was catego-
rized as current smoker or non-smoker. Drinking was cate-
gorized as current drinker or non-drinker.2.5. Definition of sarcopeniaThe height adjusted ASM (ASM/height2) was used to
define the sarcopenia cases according to the recommendation
of the Asian Working Group for Sarcopenia (AWGS) [9]. Low
muscle mass was defined as 1 standard deviation below the
mean muscle mass of the young reference group [12] instead
of 2 standard deviation as recommended by AWGS because
too small number of subjects were classified as sarcopenia
cases with this criteria. From these data, ASM/height2 (m2)
was determined to be < 7.50 kg/m2 in males and <5.38 kg/m2
in females. The lowest grip strength or gait speed quartile was
classified as low muscle strength or gait speed, respectively,
because no reference cut-off values are available for the
diagnosis of sarcopenia in Korean individuals.
The diagnosis of sarcopenia was based on the European
Working Group on Sarcopenia in Older People (EWGSOP)
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physical performance [13]. Sarcopenia was characterized by
reduced muscle mass and strength and poor physical
performance.2.6. Statistical analysisSubjects were grouped according to sex, and male and fe-
male data were analyzed separately. TG, fT4, TSH, and grip
strength were not normally distributed; thus, logarithmic
conversions were performed to approximate a normal
distribution.
Baseline characteristics were compared between the non-
sarcopenia and sarcopenia groups using Student’s t-tests for
continuous variables and chi-squared tests for categorical or
ordinal variables. Pearson's correlation analyses were per-
formed according to sex to determine whether fT4 or TSH was
associated with parameters related to sarcopenia (muscle
mass, grip strength, and gait speed). The fT4 and TSH data
were divided into quartiles, and the rate of sarcopenia for each
quartile was calculated according to sex. A logistic regression
analysis was used to calculate the odds ratios (ORs) for fT4
and TSH. Two models were constructed: Model 1, adjusted for
age, BMI, vitamin D, fasting glucose, log alanine amino-
transferase (ALT), and log aspartate aminotransferase (AST),
and Model 2, further adjusted for comorbidities (diabetes,Table 1






Age (y) 65.4 ± 4.2 68.3 ± 5.9
Height (cm) 167.1 ± 5.6 165.3 ± 5.3
Weight (kg) 69.8 ± 8.7 61.9 ± 7.3
Body mass index (kg/m2) 25.0 ± 2.7 22.7 ± 2.4
Waist circumference (cm) 88.5 ± 7.7 82.6 ± 11.5
Systolic blood pressure (mmHg) 124.0 ± 15.1 128.1 ± 14.8
Diastolic blood pressure (mmHg) 79.7 ± 10.0 80.2 ± 10.5
Total cholesterol (mg/dL) 188.6 ± 38.3 185.8 ± 37.6
Triglyceridea (mg/dL) 124.8 ± 75.3 116.6 ± 71.4
HDL-cholesterola (mg/dL) 47.8 ± 10.8 49.6 ± 16.5
Fasting glucose (mg/dL) 102.0 ± 18.6 110.7 ± 32.1
ASTa (IU/L) 32.2 ± 16.5 27.9 ± 10.1
ALTa (IU/L 30.1 ± 17.8 25.6 ± 13.4
Vitamin D (ng/mL) 16.5 ± 7.3 14.4 ± 6.3
BUN (mg/dL) 13.3 ± 3.6 13.3 ± 3.4
Free T4a (ng/dL) 1.21 ± 0.25 1.26 ± 0.25
TSHa (uIU/mL) 2.04 ± 1.90 2.08 ± 1.35
Muscle massb (kg/m2) 7.60 ± 0.76 6.53 ± 0.78
Grip strengtha (kg) 38.6 ± 6.6 31.7 ± 5.4
Gait speed (m/s) 1.59 ± 0.24 1.34 ± 0.22
Type 2 diabetes 15.4% 28.9%
Hypertension 49.2% 48.2%
Cardiovascular disease 6.7% 8.4%
Cerebrovascular disease 2.1% 4.8%
Current smoker 19.7% 30.9%
Current drinker 62.6% 56.1%
HDL: high density lipoprotein, AST: aspartate aminotransferase, ALT: alanine am
a Log transformed.
b Muscle mass ¼ Appendicular skeletal muscle mass/height2.hypertension, cardiovascular disease, and cerebrovascular
disease) and current smoking and drinking statuses. All sta-
tistical tests were conducted using the Statistical Package for
the Social Sciences version 19.0 (SPSS Inc., Chicago, IL,
USA). Two-sided p <0.05 were deemed to indicate statistical
significance.
3. Results
The baseline characteristics of the subjects are shown in
Table 1. Age was significantly higher in both males and fe-
males in the sarcopenia group than the non-sarcopenia group.
Height, weight, BMI, and waist circumference of males and
females were significantly lower in the sarcopenia group than
the non-sarcopenia group. Fasting glucose was significantly
higher and vitamin D levels, AST, and ALT significantly lower
in males in the sarcopenia group compared with the non-
sarcopenia group. The proportion of current smokers in the
sarcopenia group was significantly higher among females, but
not males, compared with the non-sarcopenia group. fT4
levels were significantly higher among females, but not males,
in the sarcopenia compared with the non-sarcopenia group. In
contrast, TSH levels were not significantly different between
groups in either males or females. The correlations of fT4 and
TSH levels with the components of sarcopenia are shown in






<0.001 65.5 ± 4.3 68.3 ± 4.4 <0.001
0.010 153.9 ± 5.5 150.3 ± 5.3 <0.001
<0.001 58.1 ± 8.2 48.2 ± 6.1 <0.001
<0.001 24.5 ± 3.1 21.3 ± 2.3 <0.001
<0.001 87.9 ± 8.8 81.6 ± 7.4 <0.001
0.033 125.2 ± 16.9 128.4 ± 18.2 0.297
0.718 75.1 ± 10.8 76.8 ± 10.5 0.369
0.557 206.4 ± 37.9 203.5 ± 36.1 0.678
0.355 107.6 ± 54.8 115.6 ± 74.1 0.483
0.412 54.7 ± 13.0 58.5 ± 13.9 0.118
0.039 101.6 ± 23.7 103.7 ± 31.9 0.899
0.006 30.0 ± 11.9 27.2 ± 10.1 0.054
0.017 24.2 ± 15.4 20.1 ± 9.4 0.066
0.023 15.3 ± 8.1 14.8 ± 8.1 0.736
0.995 12.2 ± 3.5 12.6 ± 3.7 0.553
0.095 1.18 ± 0.21 1.26 ± 0.22 0.047
0.536 2.67 ± 2.79 2.40 ± 1.65 0.925
<0.001 6.02 ± 0.64 4.98 ± 0.37 <0.001
<0.001 22.6 ± 4.8 18.3 ± 3.5 <0.001
<0.001 1.40 ± 0.25 1.14 ± 0.22 <0.001
0.030 12.0% 15.2% 0.744
0.729 39.3% 30.3% 0.510
0.622 7.0% 0.0% 0.242
0.305 2.3% 0.0% 0.568
0.097 1.5% 10.3% 0.011
0.360 14.6% 23.3% 0.095
inotransferase, BUN: blood urea nitrogen, TSH: thyroid stimulating hormone.
Fig. 1. Correlations between fT4 levels and sarcopenia components (muscle mass (A), grip strength (B), and gait speed (C)) according to sex.
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(r ¼ 0.139, p ¼ 0.011). In contrast, TSH was not signifi-
cantly associated with muscle mass in either sex. Nosignificant associations were found between thyroid function
(fT4 and TSH levels) and grip strength or gait speed. Fig. 3
shows differences in sarcopenia rates across fT4 and TSH
Fig. 2. Correlations between TSH levels and sarcopenia components [muscle mass (A), grip strength (B), and gait speed (C)] according to sex. TSH: thyroid
stimulating hormone.
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seen in the highest fT4 quartile in males and females, whereas
the lowest rate occurred in the second to lowest quartile in
both sexes. In contrast, the rate of sarcopenia was not signif-
icantly different across TSH quartiles in either sex. Table 2shows the risk of sarcopenia for males and females within
the upper fT4 and TSH quartiles. fT4 concentration was
significantly associated with the risk of sarcopenia in males
(Model 1: OR ¼ 1.45, 95% confidence interval
(CI) ¼ 1.11e1.89, p ¼ 0.005; Model 2: OR ¼ 1.56, 95%
Fig. 3. Differences in sarcopenia rates across fT4 and TSH quartiles. TSH: thyroid stimulating hormone.
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OR ¼ 1.53, 95% CI ¼ 1.04e2.26, p ¼ 0.031; Model 2:
OR ¼ 1.72, 95% CI ¼ 1.10e2.68, p ¼ 0.018). TSH was not
significantly associated with the risk of sarcopenia in either
sex.
4. Discussion
We found that higher fT4 levels were associated with sar-
copenia in relatively healthy elderly Koreans.
Furthermore, the fT4 concentration was highly associated
with muscle mass. Muscle function is impaired in patients
with thyrotoxicosis or hypothyroidism [10], and a previous
study found that excess thyroid hormone impaired the regen-
eration process in the mdx mouse [14]. Recently, thyroid
hormone-related impairment was shown to be the result of
massive satellite cell apoptosis, via the FoxO3/MyoD axis,
caused by the direct exposure of activated satellite cells to
circulating thyroid hormone [15]. Furthermore, a recent study
showed that reduced muscle mass and function may be asso-
ciated with elevated resting metabolic rate with declining
health in elderly individuals [16]. Thyroid hormones affect
energy expenditure, particularly resting metabolic rate [17].
Although we did not measure the metabolic rate of the sub-
jects, the reduced muscle mass observed in our study may beTable 2
Odds ratios (ORs) for sarcopenia in the upper fT4 and TSH quartiles.
Model fT4 ng/dL TSH uIU/L
OR 95% CI p OR 95% CI p
Males
Model 1 1.45 1.11e1.89 0.005 0.96 0.75e1.23 0.761
Model 2 1.56 1.17e2.07 0.003 0.95 0.73e1.24 0.722
Females
Model 1 1.53 1.04e2.26 0.031 1.00 0.69e1.44 0.981
Model 2 1.72 1.10e2.68 0.018 0.87 0.58e1.31 0.510
Model 1: Adjustment for age, BMI, vitamin D, fasting glucose, log ALT, and
log AST.
Model 2: Adjustment for age, BMI, vitamin D, fasting glucose, log ALT, log
AST, comorbidities (diabetes, hypertension, cardiovascular disease, and ce-
rebrovascular disease) and current smoking and drinking statuses.
ALT: alanine aminotransferase, st: aspartate aminotransferase, BMI: body
mass index, TSH: thyroid stimulating hormoneindirectly attributed to an increase in resting metabolic rate
resulting from high fT4 levels.
We found no association between sarcopenia rate and TSH
levels. The thyroid hormone physiology of elderly individuals
differs from that of younger individuals. Thus the TSH dis-
tribution curve in older adults shifts to higher values compared
with younger adults [18]. Two longitudinal studies showed an
increase in serum TSH levels with ageing, but no change in
fT4 concentrations [19,20]. Thus, changes in serum TSH
levels may not reflect thyroid disease in elderly individuals. In
fact, fT4, but not TSH, has been associated with all-cause
mortality [21,22]. TSH concentrations reflect the pituitary
effects of thyroid hormones, which may differ from end-organ
effects. A previous study found that TSH was strongly asso-
ciated with outcomes affecting the brain (i.e., dementia),
whereas the fT4 associations were strongest for outcomes
directly involving the heart (atrial fibrillation and heart failure)
[23]. A previous study in elderly Koreans found that increased
TSH levels were not associated with sarcopenia, and that
subclinical hypothyroidism may not be related to sarcopenia
[24]. These findings may be explained by the fact that TSH
rather than fT4 levels were measured.
We found no association between thyroid hormone levels
and grip strength or gait speed. However, a previous study
using the InCHIANTI study cohort revealed that mild excess
of thyroid hormone was associated with decreased physical
function in elderly males [25]. We enrolled subjects who had
visited a center, suggesting that they were in relatively good
health, perhaps making it difficult to reveal a clear association
between thyroid hormone levels and physical function. The
association between thyroid hormone levels and physical
function needs to be re-evaluated in the general population.
Several studies have found an association between mor-
tality and fT4 levels [21,22]. Sarcopenia is a risk factor for
mortality [26]. Although, multiple morbidities, such as atrial
fibrillation and heart failure, may be related to high thyroid
hormone levels, sarcopenia resulting from high fT4 concen-
trations may contribute to mortality rate in elderly individuals.
Our study has several strengths. Although several experi-
mental studies have investigated the effect of thyroid hormone
levels on muscle function, few have examined the relationship
between muscle function and thyroid hormone levels in
133Y.J. Choi et al. / Osteoporosis and Sarcopenia 1 (2015) 127e133humans. Furthermore, to our knowledge, no study has reported
an association between sarcopenia diagnosed according to the
EWGSOP criteria and thyroid hormone concentrations in an
elderly Asian population.
Our study has some limitations. First, we used a cross-
sectional design; thus, although we were able to demonstrate
associations between sarcopenia and thyroid hormone levels,
we were not able to establish causal relationships. Second, we
recruited participants who had visited a screening center; thus,
our study population was not representative of the general
population. However, our finding of a significant association
between fT4 levels and sarcopenia in a small sample of rela-
tively healthy elderly individuals is meaningful. Third, we did
not obtain second measurements of circulating TSH and fT4
concentrations; thus, we cannot rule out the possibility that the
changes in TSH levels may have been transient in some pa-
tients. Fourth, nutrition and physical activity are two major
determinants of muscle mass. Regretfully, we did not measure
these parameters. Fifth, sex hormones, especially testosterone
are important determinants of muscle mass. Sex hormones
were not measured in this study. However, we did not think
that it could not significantly affect the result of this study
because thyroid hormone is not directly affected by sex
hormones.
In conclusion, higher fT4 levels, not lower TSH levels
might have an adverse effect on sarcopenia especially in
elderly people. Future prospective studies are needed to
investigate the associations of excess thyroid hormone or
replacement therapy with adverse effects on muscle mass and
physical function in the general population.
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